HRP20141230T1 - Naäśini i postupci aktivne staniäśne imunoterapije raka upotrebom tumorskih stanica usmrä†enih visokim hidrostatskim tlakom, te dendritiäśkih stanica - Google Patents
Naäśini i postupci aktivne staniäśne imunoterapije raka upotrebom tumorskih stanica usmrä†enih visokim hidrostatskim tlakom, te dendritiäśkih stanica Download PDFInfo
- Publication number
- HRP20141230T1 HRP20141230T1 HRP20141230AT HRP20141230T HRP20141230T1 HR P20141230 T1 HRP20141230 T1 HR P20141230T1 HR P20141230A T HRP20141230A T HR P20141230AT HR P20141230 T HRP20141230 T HR P20141230T HR P20141230 T1 HRP20141230 T1 HR P20141230T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- tumor cells
- preparation according
- dendritic cells
- hydrostatic pressure
- Prior art date
Links
- 210000004881 tumor cell Anatomy 0.000 title claims 14
- 210000004443 dendritic cell Anatomy 0.000 title claims 11
- 206010028980 Neoplasm Diseases 0.000 title claims 6
- 238000009931 pascalization Methods 0.000 title claims 6
- 201000011510 cancer Diseases 0.000 title claims 5
- 238000000034 method Methods 0.000 title claims 4
- 230000001413 cellular effect Effects 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 16
- 230000001640 apoptogenic effect Effects 0.000 claims 6
- 230000002706 hydrostatic effect Effects 0.000 claims 2
- 238000002255 vaccination Methods 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 230000032832 immune response to tumor cell Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 230000001338 necrotic effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (14)
1. Farmaceutski pripravak namijenjen poticanju imunosnog odgovora na tumorske stanice, naznačen time što sadrži
a) tumorske stanice koje postaju apoptotske zbog obrade visokim hidrostatskim tlakom jednakim ili većim od 100 MPa u trajanju od 10 minuta do 2 sata i
b) dendritičke stanice.
2. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što se tumorske stanice obrađuje hidrostatskim tlakom najmanje 10 minuta pod tlakom od najmanje 200 MPa.
3. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što se tumorske stanice obrađuje hidrostatskim tlakom od 200-300 MPa.
4. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što apoptotske tumorske stanice nisu nekrotične.
5. Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se tumorske stanice dobiva iz tumorskih staničnih linija.
6. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što se tumorske stanice dobiva iz tumora izoliranog iz pacijenta kojeg treba liječiti.
7. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što su nezrele dendritičke stanice opterećene s apoptotskim tumorskim stanicama obrađenim visokim hidrostatskim tlakom.
8. Farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačen time što se nezrele dendritičke stanice dobivaju leukoferezom.
9. Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što se nezrele dendritičke stanice dobivaju leukoferezom i uzgojem in vitro u prisutnosti citokina.
10. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je namijenjen upotrebi kod pacijenata oboljelih od ranog kao i kasnog stadija raka.
11. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je namijenjen upotrebi u liječenju raka, kojeg čine rak prostate, rak jajnika ili akutna limfoblastična leukemija.
12. Postupak priprave farmaceutskog pripravka u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačen time što se nezrele dendritičke stanice stavlja u kontakt s apoptotskim tumorskim stanicama obrađenim visokim hidrostatskim tlakom jednakim ili većim od 100 MPa i naknadno zrenje dendritičkih stanica.
13. Postupak priprave farmaceutskog pripravka u skladu s patentnim zahtjevom 12, naznačen time što je namijenjen upotrebi u cijepljenju od ljudskog raka koje se sastoji u stavljanju u kontakt nezrelih dendritičkih stanica s tumorskim stanicama, gdje se navedene tumorske stanice prevodi u apoptotski stadij obradom u trajanju od 10 minuta do 2 sata visokim hidrostatskim tlakom jednakim ili većim od 100 MPa, gdje su dendritičke stanice izborno zrele prije primjene farmaceutskog pripravka.
14. Postupak priprave farmaceutskog pripravka u skladu s patentnim zahtjevom 12, naznačen time što je namijenjen upotrebi u cijepljenju od ljudskog raka koje se sastoji u stavljanju u kontakt nezrelih dendritičkih stanica s tumorskim stanicama dobivenim iz tumorske stanične linije, prevedenim u apoptotski stadij obradom u trajanju od 10 minuta do 2 sata visokim hidrostatskim tlakom jednakim ili većim od 100 MPa, gdje su dendritičke stanice izborno zrele prije primjene farmaceutskog pripravka.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161504387P | 2011-07-05 | 2011-07-05 | |
| EP11172622A EP2543386A1 (en) | 2011-07-05 | 2011-07-05 | Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure |
| EP12734884.5A EP2691110B1 (en) | 2011-07-05 | 2012-07-04 | Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells |
| PCT/EP2012/062950 WO2013004708A1 (en) | 2011-07-05 | 2012-07-04 | Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20141230T1 true HRP20141230T1 (hr) | 2015-02-13 |
Family
ID=50023029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141230AT HRP20141230T1 (hr) | 2011-07-05 | 2014-12-17 | Naäśini i postupci aktivne staniäśne imunoterapije raka upotrebom tumorskih stanica usmrä†enih visokim hidrostatskim tlakom, te dendritiäśkih stanica |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP6235085B2 (hr) |
| CL (1) | CL2013003282A1 (hr) |
| CY (1) | CY1115803T1 (hr) |
| HR (1) | HRP20141230T1 (hr) |
| IL (2) | IL229702A (hr) |
| MX (1) | MX2013013243A (hr) |
| ZA (1) | ZA201307886B (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2768942T (lt) | 2011-10-17 | 2020-04-10 | Massachusetts Institute Of Technology | Pristatymas į ląstelės vidų |
| SG11201601927SA (en) | 2013-08-16 | 2016-04-28 | Massachusetts Inst Technology | Selective delivery of material to cells |
| SG11201703044PA (en) | 2014-10-31 | 2017-05-30 | Massachusetts Inst Technology | Delivery of biomolecules to immune cells |
| EP3218492A4 (en) | 2014-11-14 | 2018-10-10 | Massachusetts Institute Of Technology | Disruption and field enabled delivery of compounds and compositions into cells |
| CN107250373A (zh) | 2015-01-12 | 2017-10-13 | 麻省理工学院 | 通过微流体递送实现的基因编辑 |
| CA2988996A1 (en) | 2015-07-09 | 2017-01-12 | Massachusetts Institute Of Technology | Delivery of materials to anucleate cells |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999042564A2 (en) * | 1998-02-20 | 1999-08-26 | The Rockefeller University | Apoptotic cell-mediated antigen presentation to dendritic cells |
| US8420078B2 (en) * | 2005-03-10 | 2013-04-16 | Yeda Research And Development Co. Ltd. | Methods and immunogenic cell preparations for treating antigen-associated diseases |
-
2012
- 2012-07-04 MX MX2013013243A patent/MX2013013243A/es active IP Right Grant
-
2013
- 2013-10-22 ZA ZA2013/07886A patent/ZA201307886B/en unknown
- 2013-11-14 CL CL2013003282A patent/CL2013003282A1/es unknown
- 2013-11-28 IL IL229702A patent/IL229702A/en active IP Right Grant
-
2014
- 2014-12-05 CY CY20141101015T patent/CY1115803T1/el unknown
- 2014-12-17 HR HRP20141230AT patent/HRP20141230T1/hr unknown
-
2016
- 2016-08-04 JP JP2016153454A patent/JP6235085B2/ja active Active
- 2016-09-12 IL IL24778116A patent/IL247781B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017025066A (ja) | 2017-02-02 |
| IL247781A0 (en) | 2016-11-30 |
| CL2013003282A1 (es) | 2014-10-10 |
| CY1115803T1 (el) | 2017-01-25 |
| IL247781B (en) | 2019-11-28 |
| JP6235085B2 (ja) | 2017-11-22 |
| IL229702A (en) | 2016-09-29 |
| ZA201307886B (en) | 2015-03-25 |
| IL229702A0 (en) | 2014-01-30 |
| MX2013013243A (es) | 2014-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20141230T1 (hr) | Naäśini i postupci aktivne staniäśne imunoterapije raka upotrebom tumorskih stanica usmrä†enih visokim hidrostatskim tlakom, te dendritiäśkih stanica | |
| RU2012127685A (ru) | Устройства и способы для активной клеточной иммунотерапии рака путем применения опухолевых клеток, уничтоженных при помощи высокого гидростатического давления, и дендритных клеток | |
| WO2017053889A3 (en) | Flt3 directed car cells for immunotherapy | |
| WO2016160622A3 (en) | Hla-g as a novel target for car t-cell immunotherapy | |
| WO2018089669A3 (en) | Immunotherapeutic tumor treatment method | |
| MX2013004817A (es) | Enfermedad inflamatoria. | |
| NZ616304A (en) | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses | |
| WO2013130102A3 (en) | Dual ox40 agonist/il-2 cancer therapy methods | |
| JP2013530155A5 (hr) | ||
| WO2015035250A3 (en) | Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome | |
| MX2019003134A (es) | Terapia de combinacion. | |
| WO2014183033A3 (en) | G-csf for use in treating or preventing a disease associated with aging in a patient, for administration with a stem-cell containing composition and/or an electromagnetic signal | |
| PH12014501388A1 (en) | A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv | |
| SI2941257T1 (en) | Treatment of the disease using a tolerable pharmaceutical preparation | |
| MX2020006944A (es) | Vacuna basada en celulas madre pluripotentes inducidas (ipsc) como un tratamiento profilactico y terapeutico para el cancer. | |
| NZ735160A (en) | Cell therapeutic agent for cancer treatment and combination therapy with same | |
| MY186134A (en) | Curcumin-peptide conjugates and formulations thereof | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| WO2015140172A3 (en) | A medicament for use in a method of inducing or extending a cellular cytotoxic immune response | |
| PH12021551235A1 (en) | Elacestrant in combination with abemaciclib in women with breast cancer | |
| MX2021001288A (es) | Vacunacion con microvesiculas derivadas de celulas tumorales para tratamiento de cancer. | |
| EA201591623A1 (ru) | СОЕДИНЕНИЯ, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ПУТЕМ ИНГИБИРОВАНИЯ АКТИВНОСТИ ТРФ-β | |
| WO2013096732A3 (en) | Methods of treating or preventing viral diseases by blocking interleukin-21 | |
| GB201104897D0 (en) | Method for the production of protein complexes and vaccine compositions comprising the same | |
| TW201613621A (en) | Composition for promoting growth of dermal papilla cells, pharmaceutical composition, and preparation method thereof |